The phase 1 trial aimed to evaluate the safety and efficacy of escalating AZD1390 doses with RT in brain malignancies. AZD1390 with IMRT showed manageable safety and potential as a GBM radiosensitizer; clinical trials continue. Glioblastoma multiforme (GBM), the most common primary brain cancer in adults, is an aggressive malignancy with limited life […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer …
Background Tertiary lymphoid structures (TLSs) are thought to stimulate antitumor immunity and positively impact prognosis and response to immune checkpoint blockade. In gastric cancers (GCs), however, TLSs are predominantly found in GC with poor prognosis and …
Background Patients with mismatch repair-deficient (MMRd) endometrial cancer (EC) can derive great benefit from immune checkpoint inhibitors (ICI). However not all responses and predictors of primary resistance are lacking. Methods We compared the immune tumor microenvironment of MMRd …
Background Fludarabine in combination with cyclophosphamide (FC) is the standard lymphodepletion regimen for CAR T-cell therapy (CAR T). A national fludarabine shortage in 2022 necessitated the exploration of alternative regimens with many centers employing single-agent bendamustine …
